Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: Implications for compartmental modelling and clinical usefulness

Synapse

Volumn 30, Issue 4, 1998, Pages 351-361

  Léger, Gabriel ^a   Gjedde, Albert ^a,b   Kuwabara, Hiroto ^c   Guttman, Mark ^d   Cumming, Paul ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Catechol O methyltransferase; Compartmental models; Dopa decarboxylase; Fluorodopa; Inhibitors; Kinet ics

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA; NITECAPONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MONKEY; NONHUMAN; OCCIPITAL CORTEX; PARKINSON DISEASE; PERMEABILITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; BRAIN; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; ENZYME INHIBITORS; FLUORODEOXYGLUCOSE F18; MACACA MULATTA; MALE; MODELS, NEUROLOGICAL; PENTANONES; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031734786     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199812)30:4<351::AID-SYN2>3.0.CO;2-2     Document Type: Article

References (53)

1. Bäckström, R., Honkanen, E., Pippuri, A., Kairisalo, P., Pystynen, J., Heinola, K., Nissinen, E., Lindén, I.-B., Männistö, P.T., Kaakkola, S., and Pohto, P. (1989) Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J. Med. Chem., 32:841-846.
2. 18F]-6-fluorodopa during positron emission tomography: Elimination and metabolism in carbidopa-treated subjects. Life Sci., 39:2243-2252.
3. Cedarbaum J.M., Léger, G., and Guttman, M. (1991) Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: Implications for the treatment of Parkinson's disease. Clin. Neuropharmacol., 14:330-342.
4. Cumming, P., and Gjedde, A. (1998) Compartmental analysis of dopa decarboxylase in living brain from dynamic positron emission tomograms. Synapse, 29:37-61.
5. 18F]-6-fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat. J. Neurochem., 48:601-608.
6. 18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521. Biochem. Pharmacol., 36:2527-2531.
7. Cumming, P., Brown, E., Damsma, G., and Fibiger, H.C. (1992) Formation and clearance of interstitial metabolites of dopamine and serotonin in rat striatum: An in vivo microdialysis study. J. Neurochem., 59:1905-1914.
8. 18F]FDOPA) in humans. J. Cereb. Blood Flow Metab., 13:668-675.
9. 18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. J. Neurochem., 63:1675-1682.
10. Cumming, P., Kuwabara, H., Ase, A., and Gjedde, A. (1995) Regulation of DOPA decarboxylase activity in brain of living rat. J. Neurochem., 65:1381-1390.
11. Cumming, P., Gjedde, A., and Reith, J. (1997a) Controversies arising from recent FDOPA articles [Letter]. J. Nucl. Med., 38:1267-1269.
12. Cumming, P., Ase, A., Laliberté, C., Kuwabara, H., and Gjedde, A. (1997b) In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. J. Cereb. Blood Flow Metab., 17:1254-1260.
13. Dhawan, V., Ishikawa, T., Patlak, C., Chaly, T., Robeson, W., Belakhlef, A., Margouleff, C., Mandel, F., and Eidelberg, D. (1996) Combined FDOPA and 3OMFD PET studies in Parkinson's disease. J. Nucl. Med., 37:209-216.
14. Doudet, D.J., Chan, G.L.Y., Holden, J.E., Morrison, K.S., Wyatt, R.J., and Ruth, T.J. (1997) Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology, 36:363-371.
15. Ericsson, A.D. (1971) Potentiation of the 1-dopa effect in man by use of catechol-O-methyltransferase inhibitors. J. Neurol. Sci., 14:193-197.
16. Evans, A.C., Marrett, S., Torrescorzo, J., Ku, S., and Collins, L. (1991) MRI-PET correction in three dimensions using a volume-of-interest (VOI) atlas. J. Cereb. Blood Flow Metab., 11:69-71.
17. Garnett, E.S., Firnau, G., Nahmias, C., and Chirakal, R. (1983) Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res., 280:169-171.
18. Gjedde, A. (1982) Calculation of glucose phosphorylation from brain uptake of glucose analoges in vivo: a re-examination. Brain Res. Rev., 4:237-274.
19. Gjedde, A., Reith, J., Dyve, S., Léger, G., Guttman, M., Diksic, M., Evans, A., and Kuwabara, H. (1991) Dopa decarboxylase activity of the living human brain. Proc. Natl. Acad. Soc. U.S.A. 88:2721-2725.
20. 18F]fluoro-L-dopa in rhesus monkey. Nucl. Med. Biol., 22:921-927.
21. Guttman, M., Léger, G., Reches, A., Evans, A., Kuwabara, H., Cedarbaum, J.M., and Gjedde, A. (1993) Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov. Disord., 8:298-304.
22. Holden, J.E., Doudet, D.J., Endres, C.J., Chan, G.L.Y., Morrison, K.S., Vingerhoets, F.G., Snow, B.J., Pate, B.D., Sossi, V., Buckley, K.R., and Ruth, T.J. (1997) Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase. J. Nucl. Med., 38:1568-1574.
23. 18F]Fluoro-L-DOPA metabolism in living human brain: A comparison of six analytical methods. J. Cereb. Blood Flow Metab., 13:57-69.
24. 18F]fluoro-DOPA in human positron emission tomographic studies. J. Cereb. Blood Flow Metab., 11:898-913.
25. Ishikawa, T., Dhawan, V., Chaly, T., Robeson, W., Belakhlef, A., Mandel, F., Dahl, R., Margouleff, C., and Eidelberg, D. (1996) Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: Effect of the plasma 3-O-methyldopa fraction on data analysis. J. Cereb. Blood Flow Metab., 16: 854-863.
26. Kaakkola, S., and Wurtman, R.J. (1992) Effect of COMT inhibitors on striatal dopamine metabolism: A microdialysis study. Brain Res., 587:241-249.
27. Kaakkola, S., Teräväinen, H., Ahtila, S., Rita, H., and Gordin, A. (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology, 44: 77-80.
28. Kobayashi, K., Inoui, O., Watanabe, Y., Onoe, H., and Långström, B. (1995) Difference in response of D2 receptor binding between 11C-N-methylspiperone and 11C-raclopride against anesthetics in rhesus monkey brain. J. Neural. Trans. [Gen], 100:147-151.
29. 18F]fluoro-DOPA and positron emission tomography: Error analysis and application to normal subjects. J. Cereb. Blood Flow Metab., 13:43-56.
30. 18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology, 42:199-203.
31. Lindén, I.-B., Nissinen, E., Etemadzadeh, E., Kaakkola, S., Männistö, P., and Pohto, P. (1988) Favourable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J. Pharmacol. Exp. Ther., 247:289-293.
32. 18F]fluoro-L-dopa. J. Label. Comp. Radiopharm., 23:1066-1067.
33. Männistö, P.T., and Kaakkola, S. (1989) New selective COMT inhibitors: Useful adjuncts for Parkinson's disease? [Review]. Trends Pharmacol. Sci., 10:54-56.
34. Männistö, P.T., Kaakkola, S., Nissinen, E., Lindén, I-B., and Pohto, P. (1988) Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci., 43:1465-1471.
35. Mantz, J., Varlet, C., Lecharny, J.B., Henzel, D., Lenot, P., and Desmonts, J.M. (1994) Effects of volatile anesthetics, thiopental, and ketamine on spontaneous and depolarization-evoked dopamine release from striatal synaptosomes in the rat. Anesthesiology, 80:352-363.
36. Martin, W.R.W., Palmer, M.R., Patlak, C.S., and Calne, D.B. (1989) Nigrostriatal function in humans studied with positron emission tomography. Ann. Neurol., 26:535-542.
37. 3H]DOPA in rats. Biochem. Pharmacol., 39:1853-1860.
38. 18F]-6-fluoro-L-DOPA in rats, monkeys and humans. Life Sci., 47:149-157.
39. Messiha, F.S., Hsu, T.H., and Bianchine, J.R. (1972) Effects of peripheral aromatic-L-amino acid decarboxylase inhibitors on L-[1-14C]-3,4-dihydroxyphenylalanine metabolism in man. Biochem. Pharmacol., 21:2144-2147.
40. 18F]Fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Brain Res., 626:1-13.
41. Nissinen, E., Lindén, I.-B., Schultz, E., and Pohto, P. (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedbergs Arch. Pharmacol., 346:262-266.
42. Nutt, J.G., and Fellman, J.H. (1984) Pharmacokinetics of levodopa [Review]. Clin. Neuropharmacol., 7:35-49.
43. Nutt, J.G., Woodward, W.R., Beckner, R.M., Stone, C.K., Berggren, K., Carter, J.H., Gancher, S.T., Hammerstad, J.P., and Gordin, A. (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology, 44:913-919.
44. Patlak, C.S., Blasberg, R.G., and Fenstermacher, J.D. (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab., 3:1-7.
45. 18F]fluoro-L-dopa. Eur. J. Pharmacol., 257:53-58.
46. 18F]fluoro-L-DOPA uptake in rhesus monkey: Pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. Brain Res., 767:45-54.
47. 18F]fluoro-L-dopa in rat. J. Cereb. Blood Flow Metab., 10:707-719.
48. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J. Neural. Transm. [PD Sect] 10:91-106.
49. 18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: Differing response in relation to presynaptic dopaminergic dysfunction. Synapse, 27:336-346.
50. Sato, K., Wu, J., Kikuchi, T., Wang, Y., Watanabe, I., and Okumura, F. (1996) Differential effects of ketamine and pentobarbitone on acetylcholine release from the rat hippocampus and striatum. Br. J. Anesthesia, 77:381-384.
51. 18F]-6 L-fluorodopa metabolism: Implications for levodopa therapy in Parkinson's disease. Neurology, 44:1292-1297.
52. 18F]fluoro-L-dopa and O-methyl-dopa in healthy humans. In: Quantification of Brain Function Using PET. R. Myers, V. Cunningham, D. Bailey, and T. Jones, eds. Academic Press, Toronto, pp. 224-226.
53. Wahl, L., and Nahmias, C. (1996) Modeling of fluorine 18-6-fluoro-L-dopa in humans. J. Nucl. Med., 37:432-437.